Publications
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy2018 | Second Faculty of Medicine
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy2016 | Second Faculty of Medicine
- Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy2016 | Second Faculty of Medicine
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications2016 | Second Faculty of Medicine
- Trial Watch: Adoptive cell transfer for oncological indications2015 | Second Faculty of Medicine
- Trial watch: Dendritic cell-based anticancer therapy2014 | Second Faculty of Medicine
- Classification of current anticancer immunotherapies2014 | Second Faculty of Medicine
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...
